Literature DB >> 1105628

Effect of ECT and imipramine treatment on the concentration of 5-hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) in the cerebrospinal fluid of depressed patients.

A Jori, E Dolfini, C Casati, G Argenta.   

Abstract

The influence of probenecid administration on 5HIAA and HVA concentrations in the CSF of depressed patients, was studied before and after treatment with imipramine or ECT. The average increase of the two metabolites in the CSF after probenecid was similar in the untreated depressed patients and in the same patients improved after both imipramine or ECT treatment. The treatment determined a significant increase in the CSF concentration of the acid metabolites also before the probenecid administration.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1105628     DOI: 10.1007/bf00421189

Source DB:  PubMed          Journal:  Psychopharmacologia


  5 in total

1.  Alterations of cerebrospinal fluid 5-hydroxyindoleacetic acid, and total blood serotonin content during clozapine treatment.

Authors:  C M Banki
Journal:  Psychopharmacology (Berl)       Date:  1978-03-01       Impact factor: 4.530

2.  Platelet serotonin transport after a single ECT.

Authors:  J L Rausch; C L Rich; S C Risch
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Correlation of anxiety and related symptoms with cerebrospinal fluid 5-hydroxyindoleacetic acid in depressed women.

Authors:  C M Banki
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

4.  5-hydroxytryptamine and depression: a model for the interaction of normal variance with pathology.

Authors:  F K Goodwin; R M Post
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

Review 5.  Non-Invasive Brain Stimulation Effects on Biomarkers of Tryptophan Metabolism: A Scoping Review and Meta-Analysis.

Authors:  Cristian G Giron; Tim T Z Lin; Rebecca L D Kan; Bella B B Zhang; Suk Yu Yau; Georg S Kranz
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.